AUR 105
Alternative Names: AUR-105Latest Information Update: 15 Jan 2024
At a glance
- Originator Aurigene Discovery Technologies
- Developer Aurigene Oncology
- Class Antineoplastics; Small molecules
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hodgkin's disease; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 30 Nov 2022 Phase-I clinical trials in Hodgkin's disease (In adults, In the elderly) in India (PO) (NCT05605119)
- 30 Nov 2022 Phase-I clinical trials in Non-Hodgkin's lymphoma (In adults, In the elderly) in India (PO) (NCT05605119)
- 30 Nov 2022 Phase-I clinical trials in Solid tumours (In adults, In the elderly) in India (PO) (NCT05605119)